



DIVISION OF  
CORPORATION FINANCE

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

October 3, 2019

Terren Peizer  
Chairman and Chief Executive Officer  
BioVie Inc.  
2120 Colorado Avenue #230  
Santa Monica, CA 90404

**Re: BioVie Inc.**  
**Amendment No. 4 to Registration Statement on Form S-1**  
**Filed October 2, 2019**  
**File No. 333-231136**

Dear Mr. Peizer:

We have reviewed your amended registration statement and have the following comment. In our comment, we may ask you to provide us with information so we may better understand your disclosure.

Please respond to this letter by amending your registration statement and providing the requested information. If you do not believe our comment applies to your facts and circumstances or do not believe an amendment is appropriate, please tell us why in your response.

After reviewing any amendment to your registration statement and the information you provide in response to the comment, we may have additional comments.

Amendment No. 4 to Registration Statement on Form S-1 filed on October 2, 2019

Description of Capital Stock

Warrants to be Issued in this Offering

Exchange Listing, page 52

1. We note your disclosure that no assurance can be given that you will be successful in listing the warrants on Nasdaq. Please clarify here and on the cover page whether the offering is contingent on your securing listing approval for the warrants.

Terren Peizer  
BioVie Inc.  
October 3, 2019  
Page 2

Please contact Christine Westbrook at 202-551-5019 or Mary Beth Breslin at 202-551-3625 with any questions.

Sincerely,

Division of Corporation Finance  
Office of Life Sciences

cc: Mitchell S. Nussbaum, Esq.